WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1

Belali, Tareg; Wodi, Chigeru; Clark, Bethany; Cheung, Man Kim; Craig, Tim J.; Wheway, Gabrielle; Wagner, Nicole; Wagner, Kay Dietrich; Roberts, Stefan; Porazinski, Sean; Ladomery, Michael

doi:10.1016/j.bbagrm.2020.194642

All Outputs (3)

SPHINX-based combination therapy as a potential novel treatment strategy for acute myeloid leukaemia (2023)
Journal Article

Introduction: Dysregulated alternative splicing is a prominent feature of cancer. The inhibition and knockdown of the SR splice factor kinase SRPK1 reduces tumour growth in vivo. As a result several SPRK1 inhibitors are in development including SPHIN... Read More about SPHINX-based combination therapy as a potential novel treatment strategy for acute myeloid leukaemia.

Targeting the splice factor kinases SRPK1 and CLK1 in leukaemia (2021)
Thesis

This study was aimed at investigating the effect of inhibiting SRPK1 in leukaemic cells. It was also aimed at exploring the potential utility of combining conventional leukaemia chemotherapy (such as imatinib) with compounds that inhibit SRPK1.

SR... Read More about Targeting the splice factor kinases SRPK1 and CLK1 in leukaemia.

WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1 (2020)
Journal Article

Dysregulated alternative splicing plays a prominent role in all hallmarks of cancer. The splice factor kinase SRPK1 drives the activity of oncogenic splice factors such as SRSF1. SRSF1 in turn promotes the expression of splice isoforms that favour tu... Read More about WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1.